BR112018016475A2 - tetrahydroisoquinoline derivatives - Google Patents

tetrahydroisoquinoline derivatives

Info

Publication number
BR112018016475A2
BR112018016475A2 BR112018016475-5A BR112018016475A BR112018016475A2 BR 112018016475 A2 BR112018016475 A2 BR 112018016475A2 BR 112018016475 A BR112018016475 A BR 112018016475A BR 112018016475 A2 BR112018016475 A2 BR 112018016475A2
Authority
BR
Brazil
Prior art keywords
compound
salt
alkyl
group
disease
Prior art date
Application number
BR112018016475-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Sato Ippei
Kamikubo Takashi
Miura Masanori
Matsushima Yuji
Tanaka Hiroaki
Shiina Yasuhiro
Yamaki Susumu
Saito Tomoyuki
Kiyohara Hiroshi
Ohe Munemichi
Mihara Kayoko
Paul Morgan Bradley
Malik Fady
Emile Collibee Scott
Ashcraft Luke
Michael Warrington Jeffrey
Lu Pu-Ping
Garard Marc
Original Assignee
Cytokinetics, Incorporated
Astellas Pharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokinetics, Incorporated, Astellas Pharma Inc. filed Critical Cytokinetics, Incorporated
Publication of BR112018016475A2 publication Critical patent/BR112018016475A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • C12N2509/10—Mechanical dissociation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Wood Science & Technology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cell Biology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BR112018016475-5A 2016-02-12 2017-02-10 tetrahydroisoquinoline derivatives BR112018016475A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662285039P 2016-02-12 2016-02-12
US62/285,039 2016-02-12
PCT/US2017/017295 WO2017139526A1 (en) 2016-02-12 2017-02-10 Tetrahydroisoquinoline derivatives

Publications (1)

Publication Number Publication Date
BR112018016475A2 true BR112018016475A2 (en) 2018-12-26

Family

ID=59561239

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018016475-5A BR112018016475A2 (en) 2016-02-12 2017-02-10 tetrahydroisoquinoline derivatives

Country Status (34)

Country Link
US (5) US9914741B2 (https=)
EP (2) EP4032877A1 (https=)
JP (2) JP6832943B2 (https=)
KR (1) KR20180120701A (https=)
CN (2) CN109069498B (https=)
AR (1) AR107592A1 (https=)
AU (1) AU2017217663B2 (https=)
BR (1) BR112018016475A2 (https=)
CA (1) CA3012839A1 (https=)
CL (1) CL2018002287A1 (https=)
CO (1) CO2018007920A2 (https=)
CY (1) CY1125222T1 (https=)
DK (1) DK3413892T3 (https=)
ES (1) ES2913423T3 (https=)
HR (1) HRP20220655T1 (https=)
HU (1) HUE058820T2 (https=)
IL (1) IL261055B (https=)
LT (1) LT3413892T (https=)
MA (1) MA44018B1 (https=)
MD (1) MD3413892T2 (https=)
MX (1) MX379159B (https=)
NZ (1) NZ746311A (https=)
PH (1) PH12018501694B1 (https=)
PL (1) PL3413892T3 (https=)
PT (1) PT3413892T (https=)
RS (1) RS63240B1 (https=)
RU (1) RU2743424C2 (https=)
SG (1) SG11201806416XA (https=)
SI (1) SI3413892T1 (https=)
SM (1) SMT202200201T1 (https=)
TW (2) TWI773118B (https=)
UA (1) UA124879C2 (https=)
WO (1) WO2017139526A1 (https=)
ZA (1) ZA201804947B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018016475A2 (en) * 2016-02-12 2018-12-26 Cytokinetics, Incorporated tetrahydroisoquinoline derivatives
GB201905721D0 (en) 2019-04-24 2019-06-05 Univ Dundee Compounds
WO2022099011A1 (en) * 2020-11-06 2022-05-12 Cytokinetics, Inc. Bicyclic 1,4-diazepanones and therapeutic uses thereof
WO2025080100A1 (ko) * 2023-10-11 2025-04-17 한국화학연구원 신규한 디-아미드 화합물, 이의 제조방법, 이를 유효성분으로 포함하는 암 또는 자가면역질환의 예방 또는 치료용 약학적 조성물
CN117379425A (zh) * 2023-11-14 2024-01-12 广州日聚商贸发展有限公司 喹啉-4-羧酸在抗衰老产品以及保护肝脏、促进肝脏再生产品制备中的应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3301857A (en) 1963-08-26 1967-01-31 Hoffmann La Roche Spiro
SE368009B (https=) 1971-09-16 1974-06-17 Kabi Ab
US6492520B1 (en) * 1996-08-06 2002-12-10 Pfizer Inc Substituted pyrido-or pyrimido-containing 6,6- or 6,7-bicyclic derivatives
KR100567649B1 (ko) 1996-09-25 2006-04-05 아스트라제네카 유케이 리미티드 혈관 내피 성장 인자와 같은 성장 인자의 효과를 억제하는 퀴놀린 유도체
US6410254B1 (en) 1999-05-18 2002-06-25 Cytokinetics Compositions and assays utilizing ADP or phosphate for detecting protein modulators
US6743599B1 (en) 1999-05-18 2004-06-01 Cytokinetics, Inc. Compositions and assays utilizing ADP or phosphate for detecting protein modulators
US7202051B1 (en) 1999-05-18 2007-04-10 Cytokinetics, Inc. Compositions and assays utilizing ADP or phosphate for detecting protein modulators
US6958333B1 (en) * 1999-07-26 2005-10-25 Banyu Pharmaceutical Co., Ltd. Biarylurea derivatives
JP2001106673A (ja) * 1999-07-26 2001-04-17 Banyu Pharmaceut Co Ltd ビアリールウレア誘導体
GB0321538D0 (en) 2003-09-13 2003-10-15 Glaxo Group Ltd Therapeutically useful compounds
JP4361566B2 (ja) * 2004-04-28 2009-11-11 武田薬品工業株式会社 縮合キノリン誘導体およびその使用
WO2007075783A2 (en) * 2005-12-22 2007-07-05 Wyeth Substituted isoquinoline-1,3(2h,4h)-diones, 1-thioxo-1,4-dihydro-2h-isoquinoline-3-ones and 1,4-dihydro-3(2h)-isoquinolones and use thereof as kinase inhibitor
GB0613208D0 (en) 2006-07-03 2006-08-09 Glaxo Group Ltd Compounds
ES2558517T3 (es) 2006-08-02 2016-02-04 Cytokinetics, Inc. Ciertas entidades químicas, composiciones y métodos que comprenden imidazopirimidinas
NZ577980A (en) * 2006-12-27 2012-01-12 Sanofi Aventis Cycloalkylamine substituted isoquinolone derivatives
RU2443698C2 (ru) 2007-01-05 2012-02-27 Дайити Санкио Компани, Лимитед Конденсированное замещенное производное аминопирролидина
US8163909B2 (en) 2007-05-25 2012-04-24 Amgen Inc. Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use
JP5451646B2 (ja) * 2008-02-27 2014-03-26 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１型の阻害剤
CN101518971B (zh) * 2008-02-29 2012-07-18 E.I.内穆尔杜邦公司 聚酯叠层膜和使用该叠层膜的太阳能电池板
NZ592008A (en) * 2008-10-02 2011-12-22 Taisho Pharmaceutical Co Ltd 7-piperidinoalkyl-3,4-dihydroquinolone derivative
CN102256493A (zh) 2008-10-29 2011-11-23 迪赛孚尔制药有限公司 表现出抗癌活性和抗增殖活性的环丙烷酰胺及其类似物
WO2010131145A1 (en) 2009-05-12 2010-11-18 Pfizer Limited Cyclobutenedione derivatives
US9133123B2 (en) 2010-04-23 2015-09-15 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
US8933072B2 (en) 2010-06-16 2015-01-13 Vitae Pharmaceuticals, Inc. Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use
CN103476757A (zh) * 2011-02-18 2013-12-25 阿勒根公司 作为磷酸二酯酶10(pde10a)的抑制剂的取代的6,7-二烷氧基-3-异喹啉醇衍生物
US8759380B2 (en) 2011-04-22 2014-06-24 Cytokinetics, Inc. Certain heterocycles, compositions thereof, and methods for their use
HUP1100241A3 (en) 2011-05-06 2013-12-30 Richter Gedeon Nyrt Oxetane substituted pyrimidones
SG10201701101YA (en) 2012-04-02 2017-04-27 Cytokinetics Inc Methods for improving diaphragm function
CN111840294A (zh) 2012-04-11 2020-10-30 赛特凯恩蒂克公司 改善对骨骼肌疲劳的抵抗力的方法
AR091699A1 (es) * 2012-07-10 2015-02-25 Astellas Pharma Inc Derivado de indol carboxamida
HUE057533T2 (hu) 2014-04-29 2022-05-28 Cytokinetics Inc Eljárások vitálkapacitás csökkenésének gátlására
JP6573618B2 (ja) 2014-09-09 2019-09-11 アステラス製薬株式会社 尿失禁予防用及び／又は治療用新規医薬組成物
BR112018016475A2 (en) * 2016-02-12 2018-12-26 Cytokinetics, Incorporated tetrahydroisoquinoline derivatives

Also Published As

Publication number Publication date
HRP20220655T1 (hr) 2022-06-24
PH12018501694A1 (en) 2019-01-28
US20170233402A1 (en) 2017-08-17
PH12018501694B1 (en) 2023-08-30
CN109069498B (zh) 2021-08-17
CO2018007920A2 (es) 2018-12-14
UA124879C2 (uk) 2021-12-08
US10689393B2 (en) 2020-06-23
AU2017217663A1 (en) 2018-10-04
CN113666938A (zh) 2021-11-19
RU2743424C2 (ru) 2021-02-18
US20230125280A1 (en) 2023-04-27
JP2021073270A (ja) 2021-05-13
US20200270266A1 (en) 2020-08-27
EP3413892A1 (en) 2018-12-19
EP3413892A4 (en) 2019-08-14
ZA201804947B (en) 2024-05-30
WO2017139526A8 (en) 2018-08-16
IL261055B (en) 2021-03-25
AR107592A1 (es) 2018-05-16
IL261055A (en) 2018-10-31
JP7137650B2 (ja) 2022-09-14
WO2017139526A1 (en) 2017-08-17
JP6832943B2 (ja) 2021-02-24
CN109069498A (zh) 2018-12-21
CY1125222T1 (el) 2025-03-28
SG11201806416XA (en) 2018-08-30
TW202138373A (zh) 2021-10-16
US9914741B2 (en) 2018-03-13
TW201741316A (zh) 2017-12-01
ES2913423T3 (es) 2022-06-02
US11479561B2 (en) 2022-10-25
DK3413892T3 (da) 2022-05-23
MX2018009759A (es) 2018-11-29
KR20180120701A (ko) 2018-11-06
SI3413892T1 (sl) 2022-06-30
CL2018002287A1 (es) 2019-01-04
MD3413892T2 (ro) 2022-06-30
JP2019509267A (ja) 2019-04-04
US20190194220A1 (en) 2019-06-27
RS63240B1 (sr) 2022-06-30
AU2017217663B2 (en) 2021-06-17
HUE058820T2 (hu) 2022-09-28
MX379159B (es) 2025-03-10
RU2018130002A3 (https=) 2020-03-24
CA3012839A1 (en) 2017-08-17
SMT202200201T1 (it) 2022-07-21
US10259821B2 (en) 2019-04-16
TWI719138B (zh) 2021-02-21
LT3413892T (lt) 2022-06-10
EP3413892B1 (en) 2022-04-20
PT3413892T (pt) 2022-05-30
US20180148458A1 (en) 2018-05-31
MA44018B1 (fr) 2022-05-31
TWI773118B (zh) 2022-08-01
MA44018A (fr) 2018-12-19
NZ746311A (en) 2022-08-26
EP4032877A1 (en) 2022-07-27
PL3413892T3 (pl) 2022-06-13
RU2018130002A (ru) 2020-03-12

Similar Documents

Publication Publication Date Title
US20230125280A1 (en) Tetrahydroisoquinoline derivatives
CN101677569A (zh) 2-氰基苯基稠合杂环化合物及其组合物和用途
JP2020506878A (ja) Ｔｒｅｋ（ｔｗｉｋ関連ｋチャネル）チャネルのアクチベータ
JP2024524765A (ja) アミド化合物とその応用
DK2614824T3 (en) TRIAZOLD DERIVATIVES TO USE IN THE TREATMENT OF NEUROPATHIC PAIN AND FIBROMYALGIA
WO2022199170A1 (zh) 四环类衍生物、其制备方法和其医药上的用途
HK40077141A (en) Tetrahydroisoquinoline derivative
HK40001944B (en) Tetrahydroisoquinoline derivatives
HK40001944A (en) Tetrahydroisoquinoline derivatives
WO2025189066A1 (en) Modulators of g protein-coupled receptor 55 (gpr55)
WO2023093787A1 (zh) 苯并二氮杂䓬类化合物及其作为Rho激酶抑制剂的应用

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI N? 10196/2001, QUE MODIFICOU A LEI N? 9279/96, A CONCESS?O DA PATENTE EST? CONDICIONADA ? ANU?NCIA PR?VIA DA ANVISA. CONSIDERANDO A APROVA??O DOS TERMOS DO PARECER N? 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL N? 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVID?NCIAS CAB?VEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2631 DE 08/06/2021 POR TER SIDO INDEVIDA.

B350 Update of information on the portal [chapter 15.35 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B25A Requested transfer of rights approved

Owner name: CYTOKINETICS, INCORPORATED (US)

B25G Requested change of headquarter approved

Owner name: CYTOKINETICS, INCORPORATED (US)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2866 DE 09/12/2025.